Songsri Kasempimolporn1, Wichit Thaveekarn2, Kanyanat Promrungreang2, Orawan Khow3, Supatsorn Boonchang4, Visith Sitprija5. 1. Senior Advisory Scientist, Department of Research and Development, Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand. 2. Scientist, Department of Research and Development, Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand. 3. Senior Scientist, Department of Research and Development, Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand. 4. Laboratory Officer, Department of Research and Development, Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand. 5. Director Professor, Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand.
Abstract
INTRODUCTION: Diagnosis of Latent Tuberculosis Infection (LTBI) is difficult due to no clinical manifestations. Cases of LTBI are mostly sputum negative. The World Health Organization recommends the Tuberculin Skin Test (TST) as the current diagnostic standard for LTBI. Our previously developed serologic strip test for LTBI detection had suboptimal sensitivity. Additional Mycobacteriumtuberculosis (MTB) latency-associated antigens may improve the detection rate of LTBI. AIM: The present study aimed to optimize sensitivity of existing strip test. MATERIALS AND METHODS: A combination of recombinant latency proteins Rv2029c, Rv2031c, Rv2032, Rv2627c, Rv3133c, and Rv3716c was used to prepare the strips and evaluate the performance with the sera of patients in four well-classified categories: LTBI, active pulmonary TB, healthy TB contacts and other non-TB diseases. RESULTS: A total of 91 serum samples from various clinical categories were screened with the strips. Among clinically diagnosed LTBI patients, strip test yielded a sensitivity of 75.0%. Among clinically diagnosed non-LTBI subjects, strip test yielded 88.1% specificity. The diagnostic positive and negative predictive values for strip test in reference to various clinical contexts were 77.4% and 86.7%, respectively. CONCLUSION: Addition of the six potential latency proteins could improve the diagnostic performance of existing strip test for LTBI. The use of suitable immunodominant antigens could maximize sensitivity in the diagnosis and differentiate MTB infection status.
INTRODUCTION: Diagnosis of Latent Tuberculosis Infection (LTBI) is difficult due to no clinical manifestations. Cases of LTBI are mostly sputum negative. The World Health Organization recommends the Tuberculin Skin Test (TST) as the current diagnostic standard for LTBI. Our previously developed serologic strip test for LTBI detection had suboptimal sensitivity. Additional Mycobacteriumtuberculosis (MTB) latency-associated antigens may improve the detection rate of LTBI. AIM: The present study aimed to optimize sensitivity of existing strip test. MATERIALS AND METHODS: A combination of recombinant latency proteins Rv2029c, Rv2031c, Rv2032, Rv2627c, Rv3133c, and Rv3716c was used to prepare the strips and evaluate the performance with the sera of patients in four well-classified categories: LTBI, active pulmonary TB, healthy TB contacts and other non-TB diseases. RESULTS: A total of 91 serum samples from various clinical categories were screened with the strips. Among clinically diagnosed LTBI patients, strip test yielded a sensitivity of 75.0%. Among clinically diagnosed non-LTBI subjects, strip test yielded 88.1% specificity. The diagnostic positive and negative predictive values for strip test in reference to various clinical contexts were 77.4% and 86.7%, respectively. CONCLUSION: Addition of the six potential latency proteins could improve the diagnostic performance of existing strip test for LTBI. The use of suitable immunodominant antigens could maximize sensitivity in the diagnosis and differentiate MTB infection status.
Authors: Mark J Sartain; Richard A Slayden; Krishna K Singh; Suman Laal; John T Belisle Journal: Mol Cell Proteomics Date: 2006-08-09 Impact factor: 5.911
Authors: Eliane M S Leyten; May Young Lin; Kees L M C Franken; Annemieke H Friggen; Corine Prins; Krista E van Meijgaarden; Martin I Voskuil; Karin Weldingh; Peter Andersen; Gary K Schoolnik; Sandra M Arend; Tom H M Ottenhoff; Michèl R Klein Journal: Microbes Infect Date: 2006-06-13 Impact factor: 2.700
Authors: U Mack; G B Migliori; M Sester; H L Rieder; S Ehlers; D Goletti; A Bossink; K Magdorf; C Hölscher; B Kampmann; S M Arend; A Detjen; G Bothamley; J P Zellweger; H Milburn; R Diel; P Ravn; F Cobelens; P J Cardona; B Kan; I Solovic; R Duarte; D M Cirillo Journal: Eur Respir J Date: 2009-05 Impact factor: 16.671
Authors: Abebech Demissie; Eliane M S Leyten; Markos Abebe; Liya Wassie; Abraham Aseffa; Getahun Abate; Helen Fletcher; Patrick Owiafe; Philip C Hill; Roger Brookes; Graham Rook; Alimuddin Zumla; Sandra M Arend; Michel Klein; Tom H M Ottenhoff; Peter Andersen; T Mark Doherty Journal: Clin Vaccine Immunol Date: 2006-02
Authors: Roi Piñeiro; María José Cilleruelo; Milagros García-Hortelano; Marta García-Ascaso; Antonio Medina-Claros; María José Mellado Journal: Indian J Pediatr Date: 2012-05-13 Impact factor: 1.967
Authors: May Young Lin; Annemieke Geluk; Steven G Smith; Amanda L Stewart; Annemieke H Friggen; Kees L M C Franken; Marleen J C Verduyn; Krista E van Meijgaarden; Martin I Voskuil; Hazel M Dockrell; Kris Huygen; Tom H M Ottenhoff; Michèl R Klein Journal: Infect Immun Date: 2007-05-14 Impact factor: 3.441